[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636953":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":21,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":21,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":21,"overallStatus":41,"whyStopped":21,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with Pulmonary Fibrosis","EXPERIMENTAL","Participants with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) will receive \\[68Ga\\]CBP8 and undergo PET combined with dynamic contrast-enhanced MRI prior to and 12 weeks after starting clinically-prescribed immunosuppression for treatment of non-IPF ILD",[13,14],"Drug: [68Ga]CBP8","Drug: Gadoterate Meglumine",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","[68Ga]CBP8","Participants will receive a single intravenous injection of up to 350 MBq of \\[68Ga\\]CBP8",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Gadoterate Meglumine","Participants will receive a single intravenous injection of 0.05 mmol\u002Fkg gadoterate meglumine during DCE-MRI",[9],[27],{"name":28,"affiliation":5,"role":29},"Sydney Montesi, MD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":21,"email":34},"CONTACT","617 724 4030","sbmontesi@mgb.org",{"name":36,"role":32,"phone":37,"phoneExt":21,"email":38},"Caroline Fromson","617 643 3260","cfromson@mgh.harvard.edu",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,56],{"name":55,"role":32,"phone":37,"phoneExt":21,"email":38},"Sydney Montesi",{"name":28,"role":29,"phone":21,"phoneExt":21,"email":21},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Peter Caravan","Sponsor",[62],{"name":63,"class":64},"National Heart, Lung, and Blood Institute (NHLBI)","NIH","100636953","phase-2-advanced-imaging-to-assess-the-effect-of-immunosuppression-on-progressive-fibrosis-100636953",false,"NCT07572383","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis","Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease","Inclusion Criteria:\n\n1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.\n2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and \u002F or prednisone for clinically indicated non-IPF ILD treatment.\n3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.\n4. Forced vital capacity (FVC) of \\>\u002F= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \\>\u002F= 25% predicted on PFTs performed at Visit 1.\n\nExclusion criteria:\n\n1. Current or prior exposure to FDA approved anti-fibrotic therapy.\n2. Extent of emphysema greater than extent of fibrosis.\n3. Pregnancy or plans to become pregnant at baseline or during follow-up.\n4. Contraindications to MRI.\n5. Contraindications to receiving gadolinium-based contrast agents.\n6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.\n7. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin (only for individuals with a history of chronic kidney disease).\n8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.\n9. Respiratory infection within the prior 6 weeks.\n10. Smoking of any kind within the prior 6 months.","ALL","18 Years","80 Years",{"count":76,"type":77},15,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \\[68Ga\\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).",[83,84],"Interstitial Lung Disease","Pulmonary Fibrosis","2026-05-02",{"date":87,"type":88},"2026-05-07","ACTUAL",{"date":90,"type":77},"2026-04",{"date":92,"type":77},"2028-12-31",{"name":59,"class":6},1]